Brief: Cyclerion Therapeutics Announces Topline Phase 2 Results For sGC Stimulator Praliciguat In Heart Failure With Preserved Ejection Fraction

Korsana Biosciences

30/10/2019 11:46

Oct 30 (Reuters) - Cyclerion Therapeutics Inc  CYCN.O :
    * CYCLERION THERAPEUTICS ANNOUNCES TOPLINE PHASE 2 RESULTS
FOR SGC
STIMULATOR PRALICIGUAT IN HEART FAILURE WITH PRESERVED EJECTION
FRACTION (HFPEF)
    * CYCLERION THERAPEUTICS INC - STUDY IN HFPEF PATIENTS DID
NOT
MEET PRIMARY ENDPOINT
    * CYCLERION THERAPEUTICS INC - COMPANY DISCONTINUING
DEVELOPMENT
OF PRALICIGUAT IN HFPEF
    * CYCLERION THERAPEUTICS INC - PRALICIGUAT WAS GENERALLY
WELL
TOLERATED, AND SAFETY PROFILE SUPPORTED INVESTIGATION OF
PRALICIGUAT IN OTHER INDICATIONS
    * CYCLERION THERAPEUTICS INC - A POSITIVE TREND IN REDUCING
HBA1C
LEVELS WAS OBSERVED IN SUBSET OF PATIENTS WITH DIABETES

Source text for Eikon:  ID:nGNX4n2xLF 
Further company coverage:  CYCN.O 

 ((Reuters.Briefs@thomsonreuters.com;))